LY3502970 + Placebo

Phase 1Completed
0 watching 0 views this week๐Ÿ’ค Quiet
33
Hype Score

Development Stage

โœ“
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Overweight

Conditions

Overweight, Obesity

Trial Timeline

Sep 21, 2023 โ†’ Jul 29, 2024

About LY3502970 + Placebo

LY3502970 + Placebo is a phase 1 stage product being developed by Eli Lilly for Overweight. The current trial status is completed. This product is registered under clinical trial identifier NCT06023095. Target conditions include Overweight, Obesity.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (4)

NCT IDPhaseStatus
NCT06023095Phase 1Completed
NCT05086445Phase 1Completed
NCT05051579Phase 2Completed
NCT04426474Phase 1Completed

Competing Products

20 competing products in Overweight

See all competitors
ProductCompanyStageHype Score
TERN-601Terns PharmaceuticalsPhase 2
49
LY3457263 + Tirzepatide + PlaceboEli LillyPhase 1
33
LY3305677 + PlaceboEli LillyPhase 1
33
LY3537031 + PlaceboEli LillyPhase 1
33
Tirzepatide + Lisdexamfetamine Dimesylate + Placebo (oral) + Placebo (injection)Eli LillyPhase 2
52
Eloralintide + PlaceboEli LillyPhase 3
77
LY4064912 + LY4064912 + Placebo + PlaceboEli LillyPhase 1
33
LY3437943 + Ethinyl Estradiol + DrospirenoneEli LillyPhase 1
33
Tirzepatide + AcetaminophenEli LillyPhase 1
33
Tirzepatide + PlaceboEli LillyPhase 2
52
Eloralintide + PlaceboEli LillyPhase 3
77
LY3437943 + PlaceboEli LillyPhase 1
33
Tirzepatide + PlaceboEli LillyPhase 3
77
Eloralintide and Tirzepatide + EloralintideEli LillyPhase 1
33
Tirzepatide + PlaceboEli LillyPhase 3
77
LY3541105 + PlaceboEli LillyPhase 1
33
Retatrutide + PlaceboEli LillyPhase 2
52
LY4167586 + Placebo + LY4167586Eli LillyPhase 1
33
AZD9550 + AZD6234 + Placebo comparatorAstraZenecaPhase 2
52
pramlintide acetate + sibutramine + phentermine + placeboAstraZenecaPhase 2
52